L Capital Asia, a private equity fund backed by LVHM, has invested about NTD 750 million in DR. WU. Based in Taiwan, DR WU is a clinical skincare brand.
19 March 2014 – DR.WU Skincare (“DR.WU” or the “Company”), Taiwan’s leading clinical skincare brand, and L Capital Asia (“L Capital Asia” or the “Firm”), the Asian private equity business sponsored by LVMH Moët Hennessy Louis Vuitton S.A. (“LVMH”) are pleased to announce that L Capital Asia LLC has invested approximately NTD 750 million for a significant minority equity stake in the Company.
Founded in 2003 by renowned dermatologist Dr. Yin-Ching Wu, DR.WU is Taiwan’s leading clinical skincare brand. The Company offers skincare products focused on addressing common skin issues with an emphasis on high efficacy with no additives, no alcohol, and concentration of high grade ingredients. By leveraging its clinical heritage, DR.WU has had demonstrable success in bringing truly innovative products to its customers over the last ten years.
DR.WU’s Chairman and CEO, Eric Wu, said, “This association with the largest luxury group in the world is truly one of the major milestones in the development history of DR.WU. With our strong reputation and product offerings, we expect DR.WU to grow exponentially and extend its market presence worldwide. We believe the investment by and involvement of L Capital Asia will help us significantly accelerate our journey.”
Managing Partner of L Capital Asia, Ravi Thakran, expressed “We are excited at this opportunity to be partnering a category leader like DR.WU from a fairly well-developed and competitive market like Taiwan. I firmly believe that the combination of DR.WU’s strong product knowledge and well-established brand name, with our insights on marketing as well as our market access will make for a good case study for international market expansion.”
L Capital Asia has been working closely with the Company over the last year and highly values DR.WU’s unique brand heritage, innovative and efficacious products, and best in class management team. This powerful value proposition for its customers is reflected in the Company’s leading position in the Taiwanese market. L Capitals Asia hopes to bring a unique approach to operational and strategic enhancement to help the Company achieve its full potential as a leading Asian skincare brand. L Capital Asia, through its extensive retail resources and network, will be able to bring additional value to the Company by providing valuable insight into consumer markets, retail operations, product design, and access to international markets.
DR.WU, Taiwan’s No.1 clinical skincare brand, is a line of highly effective skincare products developed with advanced patented technologies to target various problems in Asian skins. Based on 30 years of clinical experience and extensive skincare research, the founder Dr. Ying-Chin Wu has created the technologically advanced skincare line so that patients can enjoy the same medical treatments just like having a doctor at home. Headquartered in Taipei, the Company has built a global retail and distribution network that covers over 1,200 point-of-sales across 7 countries.
About L Capital Asia
L Capital Asia invests in lifestyle consumer businesses across Asia, adopting a triple-A strategy aimed at the Aspirational, Affordable and Alternate segments. L Capital Asia focuses on businesses that will benefit from the growing discretionary consumption in emerging Asian markets, across select sectors of lifestyle consumption. L Capital Asia aims at becoming an active operational and strategic partner to the companies in its portfolio.
Get your FREE trial or subscribe now to Buyouts to find new deal opportunities, super-charge your fundraising efforts and track top managers.